British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.

Chelsea and Westminster Hospital, London, UK.
HIV Medicine (Impact Factor: 3.45). 11/2003; 4 Suppl 1:1-41.
Source: PubMed
Download full-text


Available from: Jane Anderson, Jul 04, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hydroxyurea is used in the treatment of HIV infection in combination with nucleoside analogues, 2'3'-didehydro-3'deoxythymidine (D4T), 2'3'-dideoxyinosine or abacavir. It is distributed into human CSF and is transported from the CSF to sub-ependymal brain sites, but its movement into the brain directly from the blood has not been studied. This study addressed this by a brain perfusion technique in anaesthetized guinea-pigs. The carotid arteries were perfused with an artificial plasma containing [14C]hydroxyurea (1.6 microm) and a vascular marker, [3H]mannitol (4.6 nm). Brain uptake of [14C]hydroxyurea (8.0 +/- 0.9%) was greater than [3H]mannitol (2.4 +/- 0.2%; 20-min perfusion, n = 8). CSF uptake of [14C]hydroxyurea (5.6 +/- 1.5%) was also greater than [3H]mannitol (0.9 +/- 0.3%; n = 4). Brain uptake of [14C]hydroxyurea was increased by 200 microm hydroxyurea, 90 microm D4T, 350 microm probenecid, 25 microm digoxin, but not by 120 microm hydroxyurea, 16.5-50 microm D4T, 90 microm 2'3'-dideoxyinosine or 90 microm abacavir. [14C]Hydroxyurea distribution to the CSF, choroid plexus and pituitary gland remained unaffected by all these drugs. The metabolic half-life of hydroxyurea was > 15 h in brain and plasma. Results indicate that intact hydroxyurea can cross the brain barriers, but is removed from the brain by probenecid- and digoxin-sensitive transport mechanisms at the blood-brain barrier, which are also affected by D4T. These sensitivities implicate an organic anion transporter (probably organic anion transporting polypeptide 2) and possibly p-glycoprotein in the brain distribution of hydroxyurea and D4T.
    Journal of Neurochemistry 11/2003; 87(1):76-84. DOI:10.1046/j.1471-4159.2003.01968.x · 4.24 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Antiretroviral (ARV) drugs have become the cornerstone of care and treatment for AIDS in North America, Brazil, and Europe. Twenty years into the epidemic, and more than 10 years after the introduction of ARV's, effective global treatment of AIDS, particularly in sub-Saharan Africa where the epidemic is most concentrated, is an extraordinary challenge. Guidelines and experience in anti-microbial prophylaxis, prescription and monitoring of ARV's in resource-rich countries should inform the efforts to scale-up AIDS care and treatment in Africa. Here, we review the considerable experience of ARV treatment acquired largely in the Americas and Europe, and the fledgling clinical trials and observational studies in Africa. Implementation of safe, effective, and equitable access to ARV's in Africa should be cognizant of the guidelines for ARV treatment in the Northern countries. Careful observation and operational research to accrue more African data, and evaluate regional and local solutions to this daunting challenge, will identify new approaches to scaling-up of ARV treatment.
    AIDS reviews 5(4):195-204. · 4.02 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The introduction of combination antiretroviral therapy (cART) into clinical practice for the treatment of HIV in 1995-1996 has led to dramatic reductions in mortality and morbidity. Factors linked to a positive response to therapy include a potent and tolerable regimen, good adherence and low levels of HIV drug resistance. The aims of this thesis were to investigate factors potentially associated with different responses to cART measured using virological and immunological predictive markers, and also to look at the development of toxicities to a specific regimen. The analyses were based on data from the EuroSIDA study, which is an observational cohort of 14,310 HIV-1 infected patients from Europe, Israel and Argentina. Data collected includes demographic history, CD4 cell counts, viral loads and details of all drugs taken. EuroSIDA also collects viral sequence data for its resistance database. Investigation into virological response to first-line cART across geographical regions found evidence of variation, which was most apparent in early-cART years. Virological response improved over calendar time in all regions, especially in East Europe. Neither HIV-1 subtype nor transmitted drug resistance (TDR) were found to be associated with virological response to cART, however statistical power was limited. A significantly decreased risk of virological failure was found in patients starting efavirenz compared with nevirapine, which did not appear to be explained by baseline drug resistance. Finally, incidence of abacavir discontinuation due to a hypersensitivity reaction side effect of the drug appeared to be higher in patients starting abacavir as part of first-line therapy but decreased in recent years. In conclusion, this thesis has compared a variety of different responses to antiretroviral therapy across subsets of a large heterogeneous population. It is hoped that these findings will contribute to research in monitoring trends in response to therapy and provide insight into association with the genetic variability of the virus.